Global biopharmaceutical executive with 25+ years of enterprise leadership across the US, Europe, Japan, China, and APAC. Proven record in securing diversified biotech financing, leading corporate transformation initiatives, portfolio strategy prioritization, governance, organizational leadership, and health system stakeholder engagement. Experienced in leading both early and late‑stage development companies through pivotal inflection points—including structured financings, mergers & acquisitions, delivered 15+ FDA, EMA, and PMDA approvals/launches across therapeutic areas, built high‑performing fit for future global organizations. Enthusiastic for impactful patient centric solutions, health system sustainability initiatives and refining development efficiencies to accelerate speed-to-market.
